The Intellectual Property & Science business of Thomson Reuters revealed two new clinical trial intelligence software solutions at the annual DIA meeting in Boston - Cortellis Clinical Trials Intelligence and Cortellis Site Performance Advisor.
The new solutions are designed to optimise clinical trials, decrease time to market, accelerate clinical trial development and maximise portfolio strategies for professionals in clinical operations and development, R&D benchmarking, R&D strategy, strategic resourcing, precision and translational medicine and at contract research organizations (CROs).
Clinical Trials Intelligence allow users to access and search information on more than 130,000 U.S. and global trials for biologics, diagnostics, biomarkers, medical devices and drugs targeting rare diseases. The solution also includes access to 200,000 press releases, 220,000 literature articles, 2.25 million drug development articles, 21,000 meeting abstracts, 8,000 conference reports, and transcripts of biomedical and medicinal chemistry industry analyst and investor meetings. It offers full integration with Thomson Reuters industry-leading drug pipeline content and is available via the web portal or an application programming interface (API).
Cortellis Clinical Trials Intelligence provides over a dozen dynamic visualisations that support fact-based decision making and enhance competitive positioning. It also includes a trial timeline viewer that provides an up-to-date, longitudinal view of the trial start dates, insights on trial duration trends and expected, actual or projected end dates for a given indication, company or individual drug.
Cortellis Site Performance Advisor is an integrated solution comprising the fastest recruiting sites, ideal countries for recruitment, and countries that have applicable, relevant patient populations, all of which is critical information for pharmaceutical and CRO executives. It offers powerful and dynamic analytics that easily pinpoint sites and countries connected to successful clinical trials.
